Asialo-rhuEPO as a Potential Neuroprotectant for Ischemic Stroke Treatment
| dc.contributor.author | Kittur, Farooqahmed S. | en |
| dc.contributor.author | Hung, Chiu-Yueh | en |
| dc.contributor.author | Li, P. Andy | en |
| dc.contributor.author | Sane, David C. | en |
| dc.contributor.author | Xie, Jiahua | en |
| dc.date.accessioned | 2023-04-27T14:51:10Z | en |
| dc.date.available | 2023-04-27T14:51:10Z | en |
| dc.date.issued | 2023-04-18 | en |
| dc.date.updated | 2023-04-27T13:50:32Z | en |
| dc.description.abstract | Neuroprotective drugs to protect the brain against cerebral ischemia and reperfusion (I/R) injury are urgently needed. Mammalian cell-produced recombinant human erythropoietin (rhuEPO<sup>M</sup>) has been demonstrated to have excellent neuroprotective functions in preclinical studies, but its neuroprotective properties could not be consistently translated in clinical trials. The clinical failure of rhuEPO<sup>M</sup> was thought to be mainly due to its erythropoietic activity-associated side effects. To exploit its tissue-protective property, various EPO derivatives with tissue-protective function only have been developed. Among them, asialo-rhuEPO, lacking terminal sialic acid residues, was shown to be neuroprotective but non-erythropoietic. Asialo-rhuEPO can be prepared by enzymatic removal of sialic acid residues from rhuEPO<sup>M</sup> (asialo-rhuEPO<sup>E</sup>) or by expressing human <i>EPO</i> gene in glycoengineered transgenic plants (asialo-rhuEPO<sup>P</sup>). Both types of asialo-rhuEPO, like rhuEPO<sup>M</sup>, displayed excellent neuroprotective effects by regulating multiple cellular pathways in cerebral I/R animal models. In this review, we describe the structure and properties of EPO and asialo-rhuEPO, summarize the progress on neuroprotective studies of asialo-rhuEPO and rhuEPO<sup>M</sup>, discuss potential reasons for the clinical failure of rhuEPO<sup>M</sup> with acute ischemic stroke patients, and advocate future studies needed to develop asialo-rhuEPO as a multimodal neuroprotectant for ischemic stroke treatment. | en |
| dc.description.version | Published version | en |
| dc.format.mimetype | application/pdf | en |
| dc.identifier.citation | Kittur, F.S.; Hung, C.-Y.; Li, P.A.; Sane, D.C.; Xie, J. Asialo-rhuEPO as a Potential Neuroprotectant for Ischemic Stroke Treatment. Pharmaceuticals 2023, 16, 610. | en |
| dc.identifier.doi | https://doi.org/10.3390/ph16040610 | en |
| dc.identifier.uri | http://hdl.handle.net/10919/114816 | en |
| dc.language.iso | en | en |
| dc.publisher | MDPI | en |
| dc.rights | Creative Commons Attribution 4.0 International | en |
| dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | en |
| dc.title | Asialo-rhuEPO as a Potential Neuroprotectant for Ischemic Stroke Treatment | en |
| dc.title.serial | Pharmaceutics | en |
| dc.type | Article - Refereed | en |
| dc.type.dcmitype | Text | en |